A Phase I, Open-Label, Placebo-Controlled, Challenge Study to Evaluate the Pharmacologic Activity of Topically Administered PRN473 on the Skin Reaction Induced by Challenge Agents via a Skin Prick in Participants with Immunoglobulin E-Mediated Allergies
Latest Information Update: 14 Jun 2021
Price :
$35 *
At a glance
- Drugs Atuzabrutinib (Primary)
- Indications Asthma; Autoimmune disorders; Eczema; Rhinitis
- Focus Pharmacodynamics
- 09 Jun 2021 Status changed from not yet recruiting to completed.
- 26 Jun 2020 New trial record